IL215925A0 - Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus - Google Patents

Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus

Info

Publication number
IL215925A0
IL215925A0 IL215925A IL21592511A IL215925A0 IL 215925 A0 IL215925 A0 IL 215925A0 IL 215925 A IL215925 A IL 215925A IL 21592511 A IL21592511 A IL 21592511A IL 215925 A0 IL215925 A0 IL 215925A0
Authority
IL
Israel
Prior art keywords
electrokinetically
diabetes mellitus
insulin resistance
fluid compositions
treating insulin
Prior art date
Application number
IL215925A
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of IL215925A0 publication Critical patent/IL215925A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL215925A 2009-04-27 2011-10-25 Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus IL215925A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication Number Publication Date
IL215925A0 true IL215925A0 (en) 2011-12-29

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215925A IL215925A0 (en) 2009-04-27 2011-10-25 Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus

Country Status (9)

Country Link
EP (1) EP2424507A4 (en)
JP (2) JP2012525396A (en)
CN (1) CN102413817B (en)
AU (1) AU2010241736B2 (en)
BR (1) BRPI1013992A2 (en)
CA (1) CA2758738A1 (en)
IL (1) IL215925A0 (en)
MX (1) MX2011011333A (en)
WO (1) WO2010126908A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2391419B1 (en) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Posterior segment drug delivery
CN103153316B (en) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 Composition of medicine delivering method and equipment
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
WO2012019176A2 (en) 2010-08-05 2012-02-09 Forsight Vision4 Inc. Implantable therapeutic device
JP2013533320A (en) 2010-08-12 2013-08-22 レバレジオ コーポレイション Compositions and methods for treating tauopathy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR102117282B1 (en) * 2010-11-15 2020-06-01 베링거 인겔하임 인터내셔날 게엠베하 Vasoprotective and cardioprotective antidiabetic therapy
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CA2831606A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc Small molecule delivery with implantable therapeutic device
CA2848385C (en) 2011-09-16 2021-10-26 Forsight Vision4, Inc. Methods and apparatus to exchange a fluid of an implantable device
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
CH706747A2 (en) * 2012-07-17 2014-01-31 Hanspeter Steffen Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP6385423B2 (en) 2013-03-28 2018-09-05 フォーサイト・ビジョン フォー・インコーポレーテッド Ocular graft for therapeutic substance delivery
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
WO2015099201A1 (en) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Nanobubble-containing composition and use thereof
RU2695563C2 (en) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Method and device for eye implant delivery
BR112017002466A2 (en) 2014-08-08 2017-12-05 Forsight Vision4 Inc stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods for their preparation
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
JP6674748B2 (en) * 2015-05-27 2020-04-01 花王株式会社 GLP-1 secretagogue
EP3377009B1 (en) 2015-11-20 2020-10-28 ForSight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN105878194A (en) * 2016-06-07 2016-08-24 沈阳药科大学 Glibenclamide nanocrystal preparation and preparation method thereof
CN106362166B (en) * 2016-10-27 2019-12-10 武汉大学 Function and application of tumor necrosis factor receptor-related pan-scaffold and signaling protein in treatment of fatty liver and type II diabetes
CN115607358A (en) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 One cell model and application based on exogenous histamine detection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (en) * 1990-10-02 1992-04-16 Buchholz Klaus L Use of the reaction product of a gas and a liquid, as well as process and device for producing the same
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
CA2436427A1 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20060273476A1 (en) * 2005-06-03 2006-12-07 BAGLEY David Method for oxygenating water
AU2007308840C1 (en) * 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
AU2007308838B2 (en) * 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (en) * 2006-12-26 2008-07-10 Hydrox Kk Antioxidative functional water
JP5613565B2 (en) * 2007-10-25 2014-10-22 リバルシオ コーポレイション Compositions and methods for modulating cell membrane-mediated intracellular signaling
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Also Published As

Publication number Publication date
CN102413817A (en) 2012-04-11
MX2011011333A (en) 2011-11-18
JP2015229678A (en) 2015-12-21
CN102413817B (en) 2014-12-17
JP2012525396A (en) 2012-10-22
CA2758738A1 (en) 2010-11-04
AU2010241736A1 (en) 2011-12-22
EP2424507A4 (en) 2012-10-24
AU2010241736B2 (en) 2016-01-28
WO2010126908A1 (en) 2010-11-04
BRPI1013992A2 (en) 2016-08-16
EP2424507A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
IL215925A0 (en) Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus
HRP20180667T1 (en) A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
EP2120959A4 (en) Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
IL249998B (en) Composition for use in treating insulin resistance comprising a hydantoin derivative
ZA201200224B (en) Long acting insulin composition
PL1975226T3 (en) Liquid treatment composition
ZA201202560B (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
HK1161275A1 (en) Halogen-stabilized insulin
EP2414535A4 (en) Biomarkers related to insulin resistance and methods using the same
PL2252312T3 (en) Methods for preventing or treating insulin resistance
EP2067781A4 (en) Agent for improving insulin resistance
EP2450038A4 (en) A pharmaceutical composition for treating diabetic nephropathy and the preparation method and use thereof
PT2557920E (en) Composition comprising powdered eggshell membrane for use in treating diabetes mellitus
PT2459207E (en) Pharmaceutical composition for use in treating obesity, diabetes or to increase insulin sensitivity
HK1157690A1 (en) Syringe
GB0812019D0 (en) Insulin
EP2455090A4 (en) Agent for inhibiting increase in postprandial blood insulin level
EP2103321A4 (en) Single-use syringe
HK1145453A1 (en) A pharmaceutical composition for treating diabetic nephropathy and the preparation method and use thereof
EP2189163A4 (en) A composition for treatment of diabetes mellitus and a preparation and an use thereof
EP2382992A4 (en) Pharmaceutical composition for treating obesity or diabetes
EP2331099A4 (en) Pharmaceutical compositions for the treatment of diabetes mellitus
IL209088A0 (en) Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
GB0815390D0 (en) Syringe for medical use
HU0800662D0 (en) Lighter fluid composition comprising gamma-valerolactone and use thereof